Report cover image

Global Plasma Derived Medicine Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 205 Pages
SKU # APRC20361931

Description

Summary

According to APO Research, The global Plasma Derived Medicine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Plasma Derived Medicine include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Plasma Derived Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Plasma Derived Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Plasma Derived Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Plasma Derived Medicine revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Plasma Derived Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Plasma Derived Medicine revenue, projected growth trends, production technology, application and end-user industry.

Plasma Derived Medicine Segment by Company

Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Plasma Derived Medicine Segment by Type

Albumin
Immune Globulin
Coagulation Factor
Others
Plasma Derived Medicine Segment by Application

Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Plasma Derived Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Plasma Derived Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Plasma Derived Medicine revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

205 Pages
1 Market Overview
1.1 Product Definition
1.2 Plasma Derived Medicine Market by Type
1.2.1 Global Plasma Derived Medicine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Albumin
1.2.3 Immune Globulin
1.2.4 Coagulation Factor
1.2.5 Others
1.3 Plasma Derived Medicine Market by Application
1.3.1 Global Plasma Derived Medicine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Plasma Derived Medicine Market Dynamics
2.1 Plasma Derived Medicine Industry Trends
2.2 Plasma Derived Medicine Industry Drivers
2.3 Plasma Derived Medicine Industry Opportunities and Challenges
2.4 Plasma Derived Medicine Industry Restraints
3 Global Growth Perspective
3.1 Global Plasma Derived Medicine Market Perspective (2020-2031)
3.2 Global Plasma Derived Medicine Growth Trends by Region
3.2.1 Global Plasma Derived Medicine Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Plasma Derived Medicine Market Size by Region (2020-2025)
3.2.3 Global Plasma Derived Medicine Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Plasma Derived Medicine Revenue by Players
4.1.1 Global Plasma Derived Medicine Revenue by Players (2020-2025)
4.1.2 Global Plasma Derived Medicine Revenue Market Share by Players (2020-2025)
4.1.3 Global Plasma Derived Medicine Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Plasma Derived Medicine Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Plasma Derived Medicine Key Players Headquarters & Area Served
4.4 Global Plasma Derived Medicine Players, Product Type & Application
4.5 Global Plasma Derived Medicine Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Plasma Derived Medicine Market CR5 and HHI
4.6.3 2024 Plasma Derived Medicine Tier 1, Tier 2, and Tier 3
5 Plasma Derived Medicine Market Size by Type
5.1 Global Plasma Derived Medicine Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Plasma Derived Medicine Revenue by Type (2020-2031)
5.3 Global Plasma Derived Medicine Revenue Market Share by Type (2020-2031)
6 Plasma Derived Medicine Market Size by Application
6.1 Global Plasma Derived Medicine Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Plasma Derived Medicine Revenue by Application (2020-2031)
6.3 Global Plasma Derived Medicine Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Yuanda Shuyang
7.1.1 Yuanda Shuyang Comapny Information
7.1.2 Yuanda Shuyang Business Overview
7.1.3 Yuanda Shuyang Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.1.4 Yuanda Shuyang Plasma Derived Medicine Product Portfolio
7.1.5 Yuanda Shuyang Recent Developments
7.2 Takeda
7.2.1 Takeda Comapny Information
7.2.2 Takeda Business Overview
7.2.3 Takeda Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.2.4 Takeda Plasma Derived Medicine Product Portfolio
7.2.5 Takeda Recent Developments
7.3 Weiguang Bio
7.3.1 Weiguang Bio Comapny Information
7.3.2 Weiguang Bio Business Overview
7.3.3 Weiguang Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.3.4 Weiguang Bio Plasma Derived Medicine Product Portfolio
7.3.5 Weiguang Bio Recent Developments
7.4 Tiantan Bio
7.4.1 Tiantan Bio Comapny Information
7.4.2 Tiantan Bio Business Overview
7.4.3 Tiantan Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.4.4 Tiantan Bio Plasma Derived Medicine Product Portfolio
7.4.5 Tiantan Bio Recent Developments
7.5 CBPO
7.5.1 CBPO Comapny Information
7.5.2 CBPO Business Overview
7.5.3 CBPO Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.5.4 CBPO Plasma Derived Medicine Product Portfolio
7.5.5 CBPO Recent Developments
7.6 Shuanglin Bio
7.6.1 Shuanglin Bio Comapny Information
7.6.2 Shuanglin Bio Business Overview
7.6.3 Shuanglin Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.6.4 Shuanglin Bio Plasma Derived Medicine Product Portfolio
7.6.5 Shuanglin Bio Recent Developments
7.7 RAAS
7.7.1 RAAS Comapny Information
7.7.2 RAAS Business Overview
7.7.3 RAAS Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.7.4 RAAS Plasma Derived Medicine Product Portfolio
7.7.5 RAAS Recent Developments
7.8 Nanyue Bio
7.8.1 Nanyue Bio Comapny Information
7.8.2 Nanyue Bio Business Overview
7.8.3 Nanyue Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.8.4 Nanyue Bio Plasma Derived Medicine Product Portfolio
7.8.5 Nanyue Bio Recent Developments
7.9 Hualan Bio
7.9.1 Hualan Bio Comapny Information
7.9.2 Hualan Bio Business Overview
7.9.3 Hualan Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.9.4 Hualan Bio Plasma Derived Medicine Product Portfolio
7.9.5 Hualan Bio Recent Developments
7.10 Boya Bio
7.10.1 Boya Bio Comapny Information
7.10.2 Boya Bio Business Overview
7.10.3 Boya Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.10.4 Boya Bio Plasma Derived Medicine Product Portfolio
7.10.5 Boya Bio Recent Developments
7.11 Octapharma
7.11.1 Octapharma Comapny Information
7.11.2 Octapharma Business Overview
7.11.3 Octapharma Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.11.4 Octapharma Plasma Derived Medicine Product Portfolio
7.11.5 Octapharma Recent Developments
7.12 LFB Group
7.12.1 LFB Group Comapny Information
7.12.2 LFB Group Business Overview
7.12.3 LFB Group Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.12.4 LFB Group Plasma Derived Medicine Product Portfolio
7.12.5 LFB Group Recent Developments
7.13 KM Biologics
7.13.1 KM Biologics Comapny Information
7.13.2 KM Biologics Business Overview
7.13.3 KM Biologics Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.13.4 KM Biologics Plasma Derived Medicine Product Portfolio
7.13.5 KM Biologics Recent Developments
7.14 Kedrion
7.14.1 Kedrion Comapny Information
7.14.2 Kedrion Business Overview
7.14.3 Kedrion Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.14.4 Kedrion Plasma Derived Medicine Product Portfolio
7.14.5 Kedrion Recent Developments
7.15 Grifols
7.15.1 Grifols Comapny Information
7.15.2 Grifols Business Overview
7.15.3 Grifols Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.15.4 Grifols Plasma Derived Medicine Product Portfolio
7.15.5 Grifols Recent Developments
7.16 CSL
7.16.1 CSL Comapny Information
7.16.2 CSL Business Overview
7.16.3 CSL Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.16.4 CSL Plasma Derived Medicine Product Portfolio
7.16.5 CSL Recent Developments
7.17 BPL
7.17.1 BPL Comapny Information
7.17.2 BPL Business Overview
7.17.3 BPL Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.17.4 BPL Plasma Derived Medicine Product Portfolio
7.17.5 BPL Recent Developments
7.18 Biotest
7.18.1 Biotest Comapny Information
7.18.2 Biotest Business Overview
7.18.3 Biotest Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
7.18.4 Biotest Plasma Derived Medicine Product Portfolio
7.18.5 Biotest Recent Developments
8 North America
8.1 North America Plasma Derived Medicine Revenue (2020-2031)
8.2 North America Plasma Derived Medicine Revenue by Type (2020-2031)
8.2.1 North America Plasma Derived Medicine Revenue by Type (2020-2025)
8.2.2 North America Plasma Derived Medicine Revenue by Type (2026-2031)
8.3 North America Plasma Derived Medicine Revenue Share by Type (2020-2031)
8.4 North America Plasma Derived Medicine Revenue by Application (2020-2031)
8.4.1 North America Plasma Derived Medicine Revenue by Application (2020-2025)
8.4.2 North America Plasma Derived Medicine Revenue by Application (2026-2031)
8.5 North America Plasma Derived Medicine Revenue Share by Application (2020-2031)
8.6 North America Plasma Derived Medicine Revenue by Country
8.6.1 North America Plasma Derived Medicine Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Plasma Derived Medicine Revenue by Country (2020-2025)
8.6.3 North America Plasma Derived Medicine Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Plasma Derived Medicine Revenue (2020-2031)
9.2 Europe Plasma Derived Medicine Revenue by Type (2020-2031)
9.2.1 Europe Plasma Derived Medicine Revenue by Type (2020-2025)
9.2.2 Europe Plasma Derived Medicine Revenue by Type (2026-2031)
9.3 Europe Plasma Derived Medicine Revenue Share by Type (2020-2031)
9.4 Europe Plasma Derived Medicine Revenue by Application (2020-2031)
9.4.1 Europe Plasma Derived Medicine Revenue by Application (2020-2025)
9.4.2 Europe Plasma Derived Medicine Revenue by Application (2026-2031)
9.5 Europe Plasma Derived Medicine Revenue Share by Application (2020-2031)
9.6 Europe Plasma Derived Medicine Revenue by Country
9.6.1 Europe Plasma Derived Medicine Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Plasma Derived Medicine Revenue by Country (2020-2025)
9.6.3 Europe Plasma Derived Medicine Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Plasma Derived Medicine Revenue (2020-2031)
10.2 China Plasma Derived Medicine Revenue by Type (2020-2031)
10.2.1 China Plasma Derived Medicine Revenue by Type (2020-2025)
10.2.2 China Plasma Derived Medicine Revenue by Type (2026-2031)
10.3 China Plasma Derived Medicine Revenue Share by Type (2020-2031)
10.4 China Plasma Derived Medicine Revenue by Application (2020-2031)
10.4.1 China Plasma Derived Medicine Revenue by Application (2020-2025)
10.4.2 China Plasma Derived Medicine Revenue by Application (2026-2031)
10.5 China Plasma Derived Medicine Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Plasma Derived Medicine Revenue (2020-2031)
11.2 Asia Plasma Derived Medicine Revenue by Type (2020-2031)
11.2.1 Asia Plasma Derived Medicine Revenue by Type (2020-2025)
11.2.2 Asia Plasma Derived Medicine Revenue by Type (2026-2031)
11.3 Asia Plasma Derived Medicine Revenue Share by Type (2020-2031)
11.4 Asia Plasma Derived Medicine Revenue by Application (2020-2031)
11.4.1 Asia Plasma Derived Medicine Revenue by Application (2020-2025)
11.4.2 Asia Plasma Derived Medicine Revenue by Application (2026-2031)
11.5 Asia Plasma Derived Medicine Revenue Share by Application (2020-2031)
11.6 Asia Plasma Derived Medicine Revenue by Country
11.6.1 Asia Plasma Derived Medicine Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Plasma Derived Medicine Revenue by Country (2020-2025)
11.6.3 Asia Plasma Derived Medicine Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Plasma Derived Medicine Revenue (2020-2031)
12.2 SAMEA Plasma Derived Medicine Revenue by Type (2020-2031)
12.2.1 SAMEA Plasma Derived Medicine Revenue by Type (2020-2025)
12.2.2 SAMEA Plasma Derived Medicine Revenue by Type (2026-2031)
12.3 SAMEA Plasma Derived Medicine Revenue Share by Type (2020-2031)
12.4 SAMEA Plasma Derived Medicine Revenue by Application (2020-2031)
12.4.1 SAMEA Plasma Derived Medicine Revenue by Application (2020-2025)
12.4.2 SAMEA Plasma Derived Medicine Revenue by Application (2026-2031)
12.5 SAMEA Plasma Derived Medicine Revenue Share by Application (2020-2031)
12.6 SAMEA Plasma Derived Medicine Revenue by Country
12.6.1 SAMEA Plasma Derived Medicine Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Plasma Derived Medicine Revenue by Country (2020-2025)
12.6.3 SAMEA Plasma Derived Medicine Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.